TipRanks
GlaxoSmithKline (CH:GS71)
:GS71

GlaxoSmithKline (GS71) Price & Analysis

0 Followers

GS71 Stock Chart & Stats

CHF26.12
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF26.12
CHF0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Specialty Medicines GrowthBroad-based specialty-medicine growth across HIV, respiratory and oncology reduces reliance on a single product and supports a stronger long-term mix. Double-digit performance from several launches also indicates meaningful commercial traction for GSK’s differentiated portfolio.
Pipeline And Launch MomentumThe sharp acceleration in late-stage development expands GSK’s opportunity to replenish and diversify future revenue. Multiple approvals, launches and positive clinical readouts create several potential growth drivers rather than depending only on established medicines.
Cash Generation And ProfitabilityStrong operating cash flow and free cash flow give GSK internal funding for research, launches, business development and shareholder distributions. High profitability and recent cash-flow growth provide useful resilience while the company invests heavily in its pipeline.
Bears Say
Leverage And Interest BurdenGSK’s meaningful debt load reduces financial flexibility and makes earnings more sensitive to refinancing costs. Higher interest expense, including financing related to Nuvalent, can absorb cash that could otherwise support research, acquisitions or debt reduction.
Rising Investment And Restructuring CostsAccelerated oncology investment may strengthen the pipeline, but the near-term cost burden is substantial and is growing faster than sales. Higher R&D and restructuring charges can limit operating leverage and make earnings conversion less predictable during execution.
Vaccine And Inhaler Market PressurePressure across major commercial franchises creates a drag on portfolio growth even as newer medicines expand. Shingrix faces China ordering and inventory challenges, while inhaler pricing and competition can constrain revenue quality and margin durability.

GlaxoSmithKline News

GS71 FAQ

What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was CHF26.11 and its highest was CHF26.11 in the past 12 months.
    What is GlaxoSmithKline’s market cap?
    GlaxoSmithKline’s market cap is CHF82.08B.
      When is GlaxoSmithKline’s upcoming earnings report date?
      GlaxoSmithKline’s upcoming earnings report date is Feb 03, 2027 which is in 94 days.
        How were GlaxoSmithKline’s earnings last quarter?
        GlaxoSmithKline released its earnings results on Oct 28, 2026. The company reported CHF0.603 earnings per share for the quarter, beating the consensus estimate of CHF0.555 by CHF0.047.
          Is GlaxoSmithKline overvalued?
          According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does GlaxoSmithKline pay dividends?
            GlaxoSmithKline does not currently pay dividends.
            What is GlaxoSmithKline’s EPS estimate?
            GlaxoSmithKline’s EPS estimate is 0.31.
              How many shares outstanding does GlaxoSmithKline have?
              GlaxoSmithKline has 4,045,430,700 shares outstanding.
                What happened to GlaxoSmithKline’s price movement after its last earnings report?
                GlaxoSmithKline reported an EPS of CHF0.603 in its last earnings report, beating expectations of CHF0.555. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of GlaxoSmithKline?
                  Currently, no hedge funds are holding shares in CH:GS71
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    GlaxoSmithKline

                    GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.

                    GlaxoSmithKline (GS71) Earnings & Revenues

                    GS71 Stock 12 Month Forecast

                    Average Price Target

                    CHF23.13
                    ▼(-11.45% Downside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"CHF17","34":"CHF34","21.25":"CHF21.3","25.5":"CHF25.5","29.75":"CHF29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.221381438,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF33.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.12882707617143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF23.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.76290646,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF18.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.25,25.5,29.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,26.661644726,27.208289452,27.754934178,28.301578904,28.84822363,29.394868356,29.941513082,30.488157808,31.034802534,31.58144726,32.128091986,32.674736712,{"y":33.221381438,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,25.885294390474723,25.65558878094945,25.425883171424175,25.1961775618989,24.966471952373624,24.73676634284835,24.507060733323076,24.2773551237978,24.04764951427253,23.817943904747253,23.588238295221977,23.358532685696705,{"y":23.12882707617143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,25.54945434307692,24.983908686153846,24.41836302923077,23.85281737230769,23.287271715384612,22.721726058461538,22.15618040153846,21.590634744615386,21.025089087692308,20.45954343076923,19.893997773846152,19.328452116923078,{"y":18.76290646,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.115,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1790812800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    AstraZeneca
                    ―
                    ―
                    Hikma Pharmaceuticals
                    ―
                    ―
                    Smith & Nephew
                    ―
                    ―
                    Beximco Pharmaceuticals Limited Sponsored GDR RegS
                    ―
                    ―
                    Haleon PLC
                    ―
                    ―
                    Popular Stocks